New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
09:20 EDTCVX, NTRI, BCOR, SREV, SQI, BIRT, RXII, INVN, IMMU, OPEN, AVNR, ISRG, SQNM, MRK, ECYT, RBS, AXLOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Royal Bank of Scotland (RBS), up 9%... Sequenom (SQNM), up 8.2%... Nutrisystem (NTRI), up 11.5%... American Axle (AXL), up 2.9%. ALSO HIGHER: Wynn Resorts (WYNN), up 4% after earnings, shares upgraded at Sterne Agee... Avanir (AVNR), up 3.7% after upgraded at Mizuho... RXi Pharmaceuticals (RXII), up 27.4% after announcing results from study of RXI-109... Intuitive Surgical (ISRG), up 4% after announcing accelerated share repurchase. DOWN AFTER EARNINGS: Chevron (CVX), down 1%... OpenTable (OPEN), down 3.4%... Actuate (BIRT), down 18.2%... SciQuest (SQI), down 20%... ServiceSource (SREV), down 15.2%. ALSO LOWER: Endocyte (ECYT), down 60% after announcing DSMB recommends vintafolide PROCEED trial be stopped. The drug is being developed in partnership with Merck (MRK)... Immunomedics (IMMU), down 16% after filing to sell $30M worth of common stock in a spot secondary offering... InvenSense (INVN), down 9.3% after downgraded at Needham following the company's Q4 earnings report... Blucora (BCOR), down 10% after earnings, downgrade at Craig-Hallum.
News For CVX;RBS;ECYT;MRK;SQNM;ISRG;AVNR;OPEN;IMMU;INVN;RXII;BIRT;SQI;SREV;BCOR;NTRI;AXL From The Last 14 Days
Check below for free stories on CVX;RBS;ECYT;MRK;SQNM;ISRG;AVNR;OPEN;IMMU;INVN;RXII;BIRT;SQI;SREV;BCOR;NTRI;AXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 8, 2014
16:00 EDTMRKOptions Update; September 8, 2014
Subscribe for More Information
10:25 EDTRBSHigh option volume stocks:
Subscribe for More Information
09:15 EDTRBSRoyal Bank of Scotland, Lloyds seen failing ECB review, Bloomberg reports
Subscribe for More Information
09:12 EDTRBSOn The Fly: Pre-market Movers
Subscribe for More Information
08:26 EDTRBSRBS launches IPO of Citizens Financial unit
Subscribe for More Information
September 5, 2014
16:45 EDTMRKMarket ends week little changed after mixed economic data
Subscribe for More Information
14:22 EDTRBSMitsubishi UFJ confident in U.S. growth, unlikely to buy Citizens, Reuters says
Subscribe for More Information
11:17 EDTMRKBristol-Myers files patent infringement suit against Merck
Subscribe for More Information
09:17 EDTINVNInvenSense recent price action creates attractive entry point, says RW Baird
Subscribe for More Information
08:39 EDTMRKMerck Keytruda sales to reach $5B in 2018, says BMO Capital
Subscribe for More Information
07:18 EDTRBSRegulators drafting flexible 'bail in' bond deal for large banks, Reuters says
Subscribe for More Information
September 4, 2014
15:16 EDTMRKMerck receives accelerated approval of Keytruda
Subscribe for More Information
09:02 EDTMRKMerck's relebactam granted QIDP, fast track designations by FDA
Merck announced that the U.S. Food and Drug Administration has designated relebactam -- previously known as MK-7655 -- the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product with designated Fast Track status. The QIDP and Fast Track designations apply to intravenous use of relebactam for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Relebactam is an investigational, class A and C, beta-lactamase inhibitor that is being evaluated in combination with imipenem/cilastatin in ongoing Phase 2 clinical trials for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. In preclinical studies, relebactam administered in combination with imipenem/cilastatin demonstrated antibacterial activity against a broad range of Gram-negative and beta-lactam-resistant pathogens. Merck plans to initiate Phase 3 studies with relebactam in combination with imipenem/cilastatin in 2015.
07:21 EDTMRKMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
September 3, 2014
17:25 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
16:50 EDTCVXBoardwalk Pipeline to acquire Evangeline Ethylene Pipeline for $295M cash
Subscribe for More Information
10:32 EDTSREVServiceSource management to meet with JMP Securities
Meeting to be held in San Francisco on September 8 hosted by JMP Securities.
September 2, 2014
12:18 EDTINVNInvenSense volatility at historic low as shares near record high
InvenSense overall option implied volatility of 43 is below its 26-week average of 48 according to Track Data, suggesting decreasing price movement.
11:58 EDTCVXChevron set to test support, levels to watch
Shares are down 1.1% today in a weak energy sector. At the current price of $127.99, next support is at the 10-day moving average which was last at $127.94. Resistance is at $128.96, which was the last value for the 30-day moving average. A breakdown below the 10-day would be bearish for price. Next support in that event would be at $126.42.
10:29 EDTRBSHigh option volume stocks
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use